Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Clinical trial NCT05382299 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05382299
- Sponsor
- Gilead Sciences
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-20
- Primary completion
- 2028-07-01
- Enrollment
- 623
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.